tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2021-11-1-5-8tumors-828Research ArticleОБЗОРЫ И АНАЛИТИКАREVIEWS AND ANALYSISОтсутствие гуморального иммунитета после вакцинации против SARS-CoV-2 на фоне проведения иммунотерапии и таргетной терапии по поводу диссеминированного рака яичников: клинический случай и обзор литературыNegative results of humoral immunity after anti-SARS-CoV-2 vaccination in patient with advanced ovarian cancer treated with maintenance immunotherapy and targeted therapy: a clinical case and а literature reviewРумянцевА. А.RumyantsevA. A.

Алексей А. Румянцев, кандидат медицинских наук, врач-онколог онкологического отделения лекарственных методов лечения (химиотерапевтического) №4 НИИ клинической онкологии им. академика РАН и РАМН Н.Н. Трапезникова

Москва

Aleksey A. Rumyantsev, MD, PhD, Oncologist, Oncology Department of Medicinal Methods of Treatment (Chemotherapy) No. 4

Moscow

ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияN. N. Blokhin National Medical Research Center of OncologyRussian Federation20212607202111158Copyright © Румянцев А.А., 20212021Румянцев А.А.Rumyantsev A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/828

Гам-КОВИД-Вак (Спутник V, ФГБУ «НИЦЭМ им. Н.Ф. Гамалеи» Минздрава России), комбинированная векторная вакцина для профилактики коронавирусной инфекции, вызванной вирусом SARS-CoV-2, стала первой зарегистрированной в России и в мире вакциной против данного возбудителя. Эффективность и безопасность применения препарата ГамКОВИД-Вак у онкологических пациентов неизвестна. Мы публикуем описание клинического случая отсутствия поствакцинального иммунитета после применения препарата Гам-КОВИД-Вак у онкологической пациентки, получающей таргетную и иммунотерапию в качестве поддерживающей терапии по поводу диссеминированного рака яичников, и приводим его обсуждение в рамках имеющейся доказательной базы об эффективности применения других анти-SARS-CoV-2 вакцин у онкологических пациентов.

Gam-COVID-Vac (Sputnik V, Gamaleya Research Institute of Epidemiology and Microbiology of Ministry of Health of Russian Federation) is an adenovirus viral vector vaccine for COVID-19 which became the very first vaccine against SARS-CoV-2 registered in Russia and worldwide. The vaccine efficacy and safety in cancer patients is unknown. We present a clinical case of the absence of post-vaccination immunity after the use of Gam-COVID-Vac in a patient with advanced ovarian cancer treated with maintenance targeted and immunotherapy and discuss it in the light of the available evidence base on the effectiveness of other anti-SARS CoV-2 vaccines in cancer patients.

COVID-19SARS-CoV-2Спутник Vвакцинациярак яичниковиммунотерапиятаргетная терапияSputnik Vvaccinationovarian cancerimmunotherapytargeted therapyReferencesLogunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1 / 2 studies from Russia. The Lancet. 2020;396 (10 255):887–897. doi:10.1016/S0140–6736(20)31866–3Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1 / 2 studies from Russia. The Lancet. 2020;396 (10 255):887–897. doi:10.1016/S0140–6736(20)31866–3Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, et al. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43–50. doi:10.1016j.ejca.2020.08.011Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, et al. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43–50. doi:10.1016j.ejca.2020.08.011Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021;397 (10 275):671–681. doi:10.1016/S0140–6736(21)00234–8Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021;397 (10 275):671–681. doi:10.1016/S0140–6736(21)00234–8Bucci EM, Berkhof J, Gillibert A, Gopalakrishna G, Calogero RA, Bouter LM, et al. Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial. The Lancet. 2021;397 (10 288):1881–1883. doi:10.1016/S0140–6736(21)00899–0Bucci EM, Berkhof J, Gillibert A, Gopalakrishna G, Calogero RA, Bouter LM, et al. Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial. The Lancet. 2021;397 (10 288):1881–1883. doi:10.1016/S0140–6736(21)00899–0Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, del Molino del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22 (6):765–778. doi:10.1016/S1470–2045(21)00213–8Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, del Molino del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22 (6):765–778. doi:10.1016/S1470–2045(21)00213–8Gauci M–L, Coutzac C, Houot R, Marabelle A, Lebbé C. SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC). Eur J Cancer. 2021;148:121–123. doi:10.1016/j.ejca.2021.02.003Gauci M–L, Coutzac C, Houot R, Marabelle A, Lebbé C. SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC). Eur J Cancer. 2021;148:121–123. doi:10.1016/j.ejca.2021.02.003Massarweh A, Eliakim-Raz N, Stemmer A, Levy-Barda A, Yust-Katz S, Zer A, et al. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. JAMA Oncol. Published online May 28, 2021. doi:10.1001/jamaoncol.2021.2155Massarweh A, Eliakim-Raz N, Stemmer A, Levy-Barda A, Yust-Katz S, Zer A, et al. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. JAMA Oncol. Published online May 28, 2021. doi:10.1001/jamaoncol.2021.2155

The authors declare that there are no conflicts of interest present.